Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adaptive De-escalation of Radiation Therapy Dose in HPV-Positive Oropharyngeal Carcinoma (ART) Demonstrating Favorable Mid-Treatment Response

NCT03215719 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT03215719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03215719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adaptive De-escalation of Radiation Therapy Dose in HPV-Positive Oropharyngeal Carcinoma (ART) Demonstrating Favorable Mid-Treatment Response
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Recruiting
Start date
October 18, 2017
Completion date
December 31, 2028
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hpv positive oropharyngeal squamous cell carcinoma, oropharyngeal carcinoma